| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762474991P | 2017-03-22 | 2017-03-22 | |
| US201862621356P | 2018-01-24 | 2018-01-24 | |
| PCT/US2018/023785WO2018175733A1 (en) | 2017-03-22 | 2018-03-22 | Biomarkers and car t cell therapies with enhanced efficacy |
| Publication Number | Publication Date |
|---|---|
| SG11201908719QAtrue SG11201908719QA (en) | 2019-10-30 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908719QSG11201908719QA (en) | 2017-03-22 | 2018-03-22 | Biomarkers and car t cell therapies with enhanced efficacy |
| Country | Link |
|---|---|
| US (1) | US20200087376A1 (en) |
| EP (1) | EP3600392A1 (en) |
| JP (2) | JP2020513828A (en) |
| KR (1) | KR20190127892A (en) |
| CN (1) | CN110831619A (en) |
| AU (1) | AU2018240295A1 (en) |
| BR (1) | BR112019019426A2 (en) |
| CA (1) | CA3057306A1 (en) |
| IL (1) | IL269412A (en) |
| RU (1) | RU2019133286A (en) |
| SG (1) | SG11201908719QA (en) |
| WO (1) | WO2018175733A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273283B2 (en)* | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| KR102685501B1 (en) | 2013-02-20 | 2024-07-17 | 노파르티스 아게 | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| ES2769574T3 (en) | 2013-03-15 | 2020-06-26 | Michael C Milone | Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (en) | 2013-03-16 | 2014-10-31 | Novartis Ag | CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| EP4303229A3 (en) | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| WO2016014576A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| RU2020117196A (en) | 2014-08-19 | 2020-10-15 | Новартис Аг | CHIMERIC ANTIGENIC RECEPTOR (CAR) AGAINST CD123 FOR USE IN THE TREATMENT OF MALIGNANT TUMORS |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| PT3280729T (en) | 2015-04-08 | 2022-08-01 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| JP7114457B2 (en) | 2015-04-17 | 2022-08-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Methods for Improving Efficacy and Growth of Chimeric Antigen Receptor-Expressing Cells |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN109476722A (en) | 2015-07-21 | 2019-03-15 | 诺华股份有限公司 | Methods for improving the efficacy and expansion of immune cells |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| NZ782857A (en) | 2015-12-04 | 2025-08-29 | Novartis Ag | Compositions and methods for immunooncology |
| WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| EP3574005B1 (en) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EA201992232A1 (en) | 2017-03-22 | 2020-05-14 | Новартис Аг | COMPOSITIONS AND METHODS FOR IMMUNOUNCOLOGY |
| MX2020004013A (en) | 2017-10-18 | 2021-01-08 | Novartis Ag | Compositions and methods for selective protein degradation. |
| KR20210020932A (en) | 2018-06-13 | 2021-02-24 | 노파르티스 아게 | BCMA chimeric antigen receptor and uses thereof |
| CN109517073A (en)* | 2018-11-30 | 2019-03-26 | 北京泽勤生物医药有限公司 | A kind of fusogenic peptide of targeting therapy on tumor and its application |
| US20220017888A1 (en)* | 2018-12-11 | 2022-01-20 | Kyoto University | Method for inducing deletion in genomic dna |
| US20220160751A1 (en)* | 2019-04-02 | 2022-05-26 | Yale University | Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof |
| AU2020264484A1 (en) | 2019-05-01 | 2021-11-04 | Adoc Ssf, Llc | Compositions and methods for the treatment of cancer using a CDB engineered T cell therapy |
| WO2021044378A1 (en) | 2019-09-06 | 2021-03-11 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
| IL293215A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors that bind bcma and cd19 and their uses |
| EP4065157A1 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| WO2021127261A1 (en)* | 2019-12-17 | 2021-06-24 | The General Hospital Corporation | Engineered immune cells with reduced toxicity and uses thereof |
| EP4105232A4 (en)* | 2020-02-14 | 2023-10-11 | Beijing Yongtai Ruike Biotechnology Company Ltd | IMMUNE CELLS OVEREXPRESSING THE EXTERNALLY INTRODUCED CELL SIGNALING REGULATORY FACTOR AND THEIR USE |
| CN115461070A (en)* | 2020-03-18 | 2022-12-09 | 斯坦福大学托管董事会 | Upregulation of cathepsin gene expression as an adjunct to other treatments for disease |
| US12240899B2 (en) | 2020-06-22 | 2025-03-04 | Ngm Biopharmaceuticals, Inc. | LAIR-1-binding agents and methods of use thereof |
| IL300489A (en) | 2020-08-21 | 2023-04-01 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| US12152251B2 (en) | 2020-08-25 | 2024-11-26 | Kite Pharma, Inc. | T cells with improved functionality |
| CN113234169B (en)* | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | Targeting CLL1 chimeric antigen receptor and its application |
| CN113896795B (en) | 2020-12-11 | 2022-07-15 | 广州百暨基因科技有限公司 | anti-CLL1 antibodies and uses thereof |
| US20240325535A1 (en)* | 2021-11-11 | 2024-10-03 | The Trustees Of The University Of Pennsylvania | Compositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout |
| KR102521500B1 (en)* | 2021-12-02 | 2023-04-14 | 한국화학연구원 | Immune cells with enhanced efficacy |
| CN114350665A (en)* | 2022-01-19 | 2022-04-15 | 上海优替济生生物医药有限公司 | IFN-gamma inhibitors and uses thereof |
| CN114404592A (en)* | 2022-02-09 | 2022-04-29 | 复旦大学附属中山医院 | Application of TET2 as a target in the treatment of ischemic vascular disease |
| WO2024059834A2 (en)* | 2022-09-15 | 2024-03-21 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Downregulating inos to increase car-t killing |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018003353A (en)* | 2015-09-17 | 2018-09-17 | Novartis Ag | THERAPIES WITH CART CELLS WITH IMPROVED EFFECTIVENESS. |
| Publication number | Publication date |
|---|---|
| JP2023082071A (en) | 2023-06-13 |
| RU2019133286A3 (en) | 2021-12-07 |
| RU2019133286A (en) | 2021-04-22 |
| AU2018240295A1 (en) | 2019-10-10 |
| CA3057306A1 (en) | 2018-09-27 |
| KR20190127892A (en) | 2019-11-13 |
| BR112019019426A2 (en) | 2020-05-26 |
| IL269412A (en) | 2019-11-28 |
| JP2020513828A (en) | 2020-05-21 |
| US20200087376A1 (en) | 2020-03-19 |
| CN110831619A (en) | 2020-02-21 |
| WO2018175733A1 (en) | 2018-09-27 |
| EP3600392A1 (en) | 2020-02-05 |
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201808196UA (en) | Neoantigens and methods of their use | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells | |
| SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation |